Ulcerated Necrobiosis Lipoidica Unl Epidemiology Forecast

DelveInsight’s ‘Ulcerated Necrobiosis Lipoidica (UNL) - Epidemiology Forecast–2032’ report delivers an in-depth understanding of UNL, historical and forecasted epidemiology as well as UNL trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Ulcerated Necrobiosis Lipoidica Disease Understanding

Necrobiosis lipoidica (NL) is a granulomatous disease of unknown cause in which degeneration of dermal collagen occurs. Many of the NL affected patients can lead to ulcerations, which can impair the quality of life and are also very difficult to treat. It can occur in both Type 1 and 2 diabetes, affecting the majority of patients with diabetes. NL usually appears as patches or lesions on the lower legs or shins and can also appear elsewhere on the body – such as on the upper legs, hands, arms, torso, face, or scalp – though this is rare.

 

People with NL may notice one or more shiny, raised, flushed patches of skin on the lower legs. These may also be itchy or painful, and the centers of the patches can become pale with visible blood vessels. The cause of NL is unknown. There are various theories for its occurrence. The most common theories among it involve elements of a vascular disturbance involving immune complex deposition or microangiopathic changes leading to collagen degeneration.

 

Ulcerated Necrobiosis Lipoidica Diagnosis

Although the diagnosis often is based on clinical examination, a biopsy is performed to differentiate NL from conditions with similar clinical appearances, including granuloma annulare and necrobiotic xanthogranuloma.

 

If there is a concern for venous disease or peripheral arterial disease, further studies are considered. Baseline blood work, including fasting blood glucose or glycosylated hemoglobin, to screen for diabetes or assess glycemic control in patients known to have diabetes.

Continued in the report…..

Ulcerated Necrobiosis Lipoidica Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Necrobiosis Lipoidica (NL), diagnosed Prevalence of NL by Comorbidities and diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica (UNL) scenario of Ulcerated Necrobiosis Lipoidica (UNL) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Key Findings

  • Total diagnosed prevalent cases of NL in the 7MM was found to be 254,858 in 2021, which might increase up to 2,64,597 in 2032. These cases are expected to increase at a CAGR of 0.4% during study period (2019–2032).
  • The diagnosed prevalent cases of NL were distributed on the basis of comorbidities into Diabetic NL Patients and Non Diabetic NL. As per our estimates, in 2021 the diagnosed prevalent cases of NL were more in Diabetic Patients in the 7MM.
  • The total diagnosed prevalent cases of UNL in the 7MM were observed to be 87,467 in 2021. These cases are expected to increase during the study period (2019–2032).
  • Among 7MM, the United States has the highest prevalent cases of UNL with 49,330 cases in 2021.
  • Among the European countries, Germany had the highest diagnosed prevalent population of UNL with 8,010 cases, followed by Spain with 5,913 cases in 2021. On the other hand, France had the lowest diagnosed prevalent population.
  • In Japan, 9,542 diagnosed prevalent cases of Ulcerated Necrobiosis Lipoidica were recorded in the year 2021.

Scope of the Report

  • The report covers the descriptive overview of Ulcerated Necrobiosis Lipoidica, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Ulcerated Necrobiosis Lipoidica epidemiology.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Ulcerated Necrobiosis Lipoidica is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Ulcerated Necrobiosis Lipoidica market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Ulcerated Necrobiosis Lipoidica market.

Report Highlights

  • 11-Year Forecast of Ulcerated Necrobiosis Lipoidica
  • The 7MM Coverage
  • Total Diagnosed prevalent cases of Necrobiosis Lipoidica
  • Diagnosed Prevalence of NL by Comorbidities
  • Diagnosed prevalent cases of Ulcerated Necrobiosis Lipoidica

Key Questions Answered

  • What are the disease risk and burdens of Ulcerated Necrobiosis Lipoidica?
  • What is the historical Ulcerated Necrobiosis Lipoidica patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Ulcerated Necrobiosis Lipoidica at the 7MM level?
  • What will be the growth opportunities across the 7MM concerning the patient population about Ulcerated Necrobiosis Lipoidica?
  • Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Ulcerated Necrobiosis Lipoidica during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Reasons to buy

The Ulcerated Necrobiosis Lipoidica report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the 7MM Ulcerated Necrobiosis Lipoidica epidemiology forecast.
  • The Ulcerated Necrobiosis Lipoidica epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Ulcerated Necrobiosis Lipoidica epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Ulcerated Necrobiosis Lipoidica Patient Overview at a Glance

3.1. Patient Share (%) Distribution of Ulcerated Necrobiosis Lipoidica by Therapies in 2019

3.2. Patient Share (%) Distribution of Ulcerated Necrobiosis Lipoidica by Therapies in 2032

4. Executive Summary of Ulcerated Necrobiosis Lipoidica

5. Patient Journey

6. Disease Background and Overview: Ulcerated Necrobiosis Lipoidica

6.1. Introduction

6.2. Risk Factors, Signs and Symptoms

6.3. Etiology

6.4. Pathophysiology

6.5. Diagnosis

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Methodology of Epidemiology

7.3. Assumptions and Rationale: 7MM

7.4. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the 7MM

7.5. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the 7MM

7.6. The United States

7.6.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the United States

7.6.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the United States

7.6.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the United States

7.7. Major Five European Countries

7.7.1. Germany

7.7.1.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Germany

7.7.1.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Germany

7.7.1.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Germany

7.7.2. France

7.7.2.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in France

7.7.2.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in France

7.7.2.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in France

7.7.3. Italy

7.7.3.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Italy

7.7.3.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Italy

7.7.3.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Italy

7.7.4. Spain

7.7.4.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Spain

7.7.4.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Spain

7.7.4.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Spain

7.7.5. UK

7.7.5.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the UK

7.7.5.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the UK

7.7.5.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the UK

7.8. Japan

7.8.1. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Japan

7.8.2. Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Japan

7.8.3. Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Japan

8. Key Opinion Leaders’ Views

9. Appendix

9.1. Bibliography

9.2. Report Methodology

9.3. Abbreviation

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the 7MM (2019–2032)

Table 2: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the 7MM (2019–2032)

Table 3: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the United States (2019–2032)

Table 4: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the US (2019–2032)

Table 5: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the US (2019–2032)

Table 6: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Germany (2019–2032)

Table 7: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Germany (2019–2032)

Table 8: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Germany (2019–2032)

Table 9: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in France (2019–2032)

Table 10: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in France (2019–2032)

Table 11: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in France (2019–2032)

Table 12: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Italy (2019–2032)

Table 13: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Italy (2019–2032)

Table 14: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Italy (2019–2032)

Table 15: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Spain (2019–2032)

Table 16: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Spain  (2019–2032)

Table 17: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Spain  (2019–2032)

Table 18: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the UK (2019–2032)

Table 19: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the UK (2019–2032)

Table 20: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the UK (2019–2032)

Table 21: Total Prevalent Cases of Necrobiosis Lipoidica in Japan (2019–2032)

Table 22: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Japan (2019–2032)

Table 23: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Japan (2019–2032)

Table 24: Abbreviation

List of Figures

Figure 1: Anterior Aspect of both Legs Showing Large and Ulcerative Plaques of Necrobiosis Lipoidica

Figure 2: Conditions with an increased risk of developing Necrobiosis Lipoidica

Figure 3: Complications of Necrobiosis Lipoidica

Figure 4: Clinical Manifestations and Histopathological Findings

Figure 5: Representative Section of the Patient’s Punch Biopsy

Figure 6: Approach to Necrobiosis Lipoidica

Figure 7: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the 7MM (2019–2032)

Figure 8: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the 7MM (2019–2032)

Figure 9: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the United States (2019–2032)

Figure 10: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the US (2019–2032)

Figure 11: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the US (2019–2032)

Figure 12: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Germany (2019–2032)

Figure 13: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Germany (2019–2032)

Figure 14: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Germany (2019–2032)

Figure 16: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in France (2019–2032)

Figure 17: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in France (2019–2032)

Figure 18: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in France (2019–2032)

Figure 19: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Italy (2019–2032)

Figure 20: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Italy (2019–2032)

Figure 21: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Italy (2019–2032)

Figure 22: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Spain (2019–2032)

Figure 23: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Spain (2019–2032)

Figure 24: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Spain (2019–2032)

Figure 25: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in the UK (2019–2032)

Figure 26: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in the UK (2019–2032)

Figure 27: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in the UK (2019–2032)

Figure 28: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica in Japan (2019–2032)

Figure 29: Total Diagnosed Prevalent Cases of Necrobiosis Lipoidica by Comorbidities in Japan (2019–2032)

Figure 30: Total Diagnosed Prevalent Cases of Ulcerated Necrobiosis Lipoidica in Japan (2019–2032)

Figure 31: Patient Journey

Forward to Friend

Need A Quote